Regeneron Pharmaceuticals
REGN
1,078 hedge funds and large institutions have $56.9B invested in Regeneron Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 174 funds opening new positions, 427 increasing their positions, 321 reducing their positions, and 97 closing their positions.
79% more first-time investments, than exits
New positions opened: 174 | Existing positions closed: 97
33% more repeat investments, than reductions
Existing positions increased: 427 | Existing positions reduced: 321
6% more funds holding
Funds holding: 1,019 → 1,078 (+59)
5% more capital invested
Capital invested by funds: $54.5B → $56.9B (+$2.46B)
0.67% less ownership
Funds ownership: 86.01% → 85.33% (-0.67%)
12% less funds holding in top 10
Funds holding in top 10: 17 → 15 (-2)
33% less call options, than puts
Call options by funds: $985M | Put options by funds: $1.48B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$301M |
| 2 |
Two Sigma Advisers
New York
|
+$239M |
| 3 |
Two Sigma Investments
New York
|
+$196M |
| 4 |
Dodge & Cox
San Francisco,
California
|
+$172M |
| 5 |
BlackRock
New York
|
+$150M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$618M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$532M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$218M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$162M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$143M |
REGN Hedge Fund Activity: Q4 2021 in Review
1,078 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2021, worth a combined $56.9B — up 4.5% from $54.5B a quarter earlier.
Buyers outnumbered sellers: 174 funds opened new REGN positions and 97 closed out — a net gain of 77 holders — while 427 added to existing stakes and 321 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $301M. The largest seller was Fidelity Investments, cutting an estimated $618M.
- 1,078 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2021, up from 1,019 in Q3 2021.
- Funds reported $56.9B of Regeneron Pharmaceuticals stock for Q4 2021, up 4.5% quarter-over-quarter.
- 174 funds opened new Regeneron Pharmaceuticals positions in Q4 2021 and 97 closed out, a net change of +77 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2021 was JP Morgan Chase, an estimated $301M added.
- The largest Regeneron Pharmaceuticals seller in Q4 2021 was Fidelity Investments, an estimated $618M sold.
Based on aggregated 13F filings for Q4 2021.